GlassScriptPhysician profile
Michelle V Sun
NPI 1235242405
$4,368.24
in general payments reported to CMS, 2019-2025
38 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $985 · 2020: $667 · 2021: $1,292 · 2022: $529 · 2023: $390 · 2024: $346 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $674.42 | 2019-2024 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $472.30 | 2019-2025 | Jardiance, Synjardy |
| Amarin Pharma, INC. | $385.10 | 2019-2022 | |
| Pfizer INC. | $339.87 | 2019-2025 | |
| Abbvie INC. | $305.73 | 2020-2024 | Ubrelvy, Vraylar |
| Astrazeneca Pharmaceuticals LP | $253.18 | 2019-2023 | Farxiga |
| Amgen INC. | $235.03 | 2019-2024 | Prolia, Evenity, Repatha |
| Merck Sharp & Dohme LLC | $214.04 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $190.76 | 2020-2022 | |
| Eisai INC. | $132.53 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $112.39 | 2021 | |
| Astellas Pharma US INC | $108.56 | 2021-2024 | Veozah |
| Esperion Therapeutics, INC. | $87.63 | 2020-2021 | |
| Lilly USA, LLC | $82.29 | 2020-2022 | |
| Allergan, INC. | $75.59 | 2019-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.